Cargando…

Ten Years Experience With Belatacept-Based Immunosuppression After Kidney Transplantation

BACKGROUND: Belatacept was approved for prevention of acute rejection in adult kidney transplantation in 2011 based on two randomized, controlled, multicenter phase 3 studies. Long-term experience over 10 years with belatacept-based immunosuppression after kidney transplantation has not been reporte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grannas, Gerrit, Schrem, Harald, Klempnauer, Juergen, Lehner, Frank
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3935530/ https://www.ncbi.nlm.nih.gov/pubmed/24578751 http://dx.doi.org/10.14740/jocmr1697w

Ejemplares similares

Risk-Adjusted Analysis of Relevant Outcome Drivers for Patients after More Than Two Kidney Transplants
por: Kousoulas, Lampros, et al.
Publicado: (2015)

Ten‐year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4‐weekly or 8‐weekly
por: Vincenti, F., et al.
Publicado: (2017)

Belatacept for Maintenance Immunosuppression in Lung Transplantation
por: Hui, Christine, et al.
Publicado: (2014)

Belatacept-based immunosuppressive regimen in HIV-positive kidney transplant recipients
por: El Sakhawi, Karim, et al.
Publicado: (2020)

Conversion From Belatacept to Another Immunosuppressive Regimen in Maintenance Kidney-Transplantation Patients
por: Gouin, Anna, et al.
Publicado: (2020)

Belatacept Conversion in Kidney After Liver Transplantation
por: Cristea, Octav, et al.
Publicado: (2021)

Ascites Drainage Leading to Intestinal Adhesions at the Mesentery of the Small Intestine with Fatal Outcome
por: Kettler, B., et al.
Publicado: (2014)

Prediction of Three-Year Mortality After Deceased Donor Kidney Transplantation in Adults with Pre-Transplant Donor and Recipient Variables
por: Schwager, Ysabell, et al.
Publicado: (2019)

Converting Maintenance Kidney-Transplant Patients From Belatacept to Another Immunosuppressive Regimen: A Cautionary Tale
por: Chandran, Sindhu, et al.
Publicado: (2020)

Long-Term Results After Adult Ex Situ Split Liver Transplantation Since Its Introduction in 1987
por: Schrem, Harald, et al.
Publicado: (2014)

Outcome stagnation of liver transplantation for primary sclerosing cholangitis in the Model for End-Stage Liver Disease era
por: Klose, Johannes, et al.
Publicado: (2014)

Optimization of de novo belatacept‐based immunosuppression administered to renal transplant recipients
por: Kirk, Allan D., et al.
Publicado: (2020)

Early post-transplant recurrence of ANCA vasculitis while on belatacept maintenance immunosuppression
por: Agrawal, Amogh, et al.
Publicado: (2023)

De Novo Belatacept in a Kidney-After-Heart Transplant Recipient
por: Schenk, Austin D., et al.
Publicado: (2019)

Belatacept and mediastinal histoplasmosis in a kidney transplant patient
por: Trimarchi, Hernán, et al.
Publicado: (2016)

Belatacept in kidney transplant patients with systemic lupus erythematosus
por: Carrión-Barberà, Irene, et al.
Publicado: (2019)

Time-Limited Therapy with Belatacept in Kidney Transplant Recipients
por: Letellier, Thibault, et al.
Publicado: (2022)

Development and validation of a prognostic model for kidney function 1 year after combined pancreas and kidney transplantation using pre-transplant donor and recipient variables
por: Zorn, Katharina S., et al.
Publicado: (2018)

Liver Transplantation for Hepatocellular Carcinoma: A Single Center Resume Overlooking Four Decades of Experience
por: Emmanouilidis, Nikos, et al.
Publicado: (2016)

Post-transplant aspergillosis and the role of combined neurosurgical and antifungal therapies under belatacept immunosuppression
por: Kasper, Ekkehard M., et al.
Publicado: (2011)

Belatacept-Based Immunosuppression in De Novo Liver Transplant Recipients: 1-Year Experience From a Phase II Randomized Study
por: Klintmalm, G B, et al.
Publicado: (2014)

Proposal of Two Prognostic Models for the Prediction of 10-Year Survival after Liver Resection for Colorectal Metastases
por: Kulik, Ulf, et al.
Publicado: (2018)

Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Belatacept in Adult Kidney Transplant Recipients
por: Shen, Jinshan, et al.
Publicado: (2013)

Biliary complications following liver transplantation: Single-center experience over three decades and recent risk factors
por: Kaltenborn, Alexander, et al.
Publicado: (2017)

Alloreactive CD154-expressing T-cell subsets with differential sensitivity to the immunosuppressant, belatacept: potential targets of novel belatacept-based regimens
por: Ashokkumar, Chethan, et al.
Publicado: (2015)

Comparable outcome of liver transplantation with Histidine-Tryptophan-Ketoglutarate vs. University of Wisconsin preservation solution: a retrospective observational double-center trial
por: Kaltenborn, Alexander, et al.
Publicado: (2014)

Belatacept in Kidney Transplantation: What Are the True Benefits? A Systematic Review
por: Lombardi, Yannis, et al.
Publicado: (2022)

Hepatitis B Virus Reactivation in Kidney Transplant Recipients Treated With Belatacept
por: Schwarz, Chloë, et al.
Publicado: (2023)

Belatacept in renal transplantation—quo vadis?
por: Westhoff, Timm H.
Publicado: (2016)

Conversion to belatacept after lung transplantation: Report of 10 cases
por: Brugière, Olivier, et al.
Publicado: (2023)

Belatacept conversion in African American kidney transplant recipients with severe renal dysfunction
por: Snyder, Heather S, et al.
Publicado: (2016)

Early calcineurin-inhibitor to belatacept conversion in steroid-free kidney transplant recipients
por: Tawhari, Ibrahim, et al.
Publicado: (2022)

Use of Belatacept as Alternative Immunosuppression in Three Renal Transplant Patients with De Novo Drug-Induced Thrombotic Microangiopathy
por: Cicora, Federico, et al.
Publicado: (2013)

Treatment of De Novo Renal Transplant Recipients With Calcineurin Inhibitor–free, Belatacept Plus Everolimus–based Immunosuppression
por: Peddi, V. Ram, et al.
Publicado: (2023)

Independent Pre-Transplant Recipient Cancer Risk Factors after Kidney Transplantation and the Utility of G-Chart Analysis for Clinical Process Control
por: Schrem, Harald, et al.
Publicado: (2016)

Belatacept Use after Kidney Transplantation and Its Effects on Risk of Infection and COVID-19 Vaccine Response
por: Terrec, Florian, et al.
Publicado: (2021)

The blockade of T-cell co-stimulation as a therapeutic stratagem for immunosuppression: Focus on belatacept
por: Snanoudj, Renaud, et al.
Publicado: (2007)

Influence of Belatacept- vs. CNI-Based Immunosuppression on Vascular Stiffness and Body Composition
por: Heleniak, Zbigniew, et al.
Publicado: (2022)

Matched-pair analysis: identification of factors with independent influence on the development of PTLD after kidney or liver transplantation
por: Rausch, Lisa, et al.
Publicado: (2016)

Belatacept Does Not Inhibit Follicular T Cell-Dependent B-Cell Differentiation in Kidney Transplantation
por: de Graav, Gretchen N., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_134gmg0dlfj168kprihpegqgd2